{"nctId":"NCT00509028","briefTitle":"Safety and Efficacy Study of Budesonide (Pulmicort速) Turbuhaler速 in Japanese Children With Bronchial Asthma","startDateStruct":{"date":"2006-12"},"conditions":["Asthma"],"count":241,"armGroups":[{"label":"BUD - Budesonide","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide"]},{"label":"CONV - Conventional Asthma Therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Conventional Asthma Therapy"]}],"interventions":[{"name":"Budesonide","otherNames":["Pulmicort速 Turbuhaler速"]},{"name":"Conventional Asthma Therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient who complete preceding the Phase III study and provide a signed written informed consent by patient's legal representative at Visit 1 or 4 weeks prior to Visit 1 of the study. A signed written informed assent should also be obtained from the patients themselves as much as possible\n* When the investigator will obtain the signed written informed consent of Phase III study (D5254C00769) from patient's legal representative, the investigator will also provide the information of this study\n\nExclusion Criteria:\n\n* Respiratory infections that, in the opinion of the investigator(s), may affect the efficacy evaluation e.g., lower airways infection such as pneumonia, infection with no available effective antimicrobial drugs or with deep seated mycosis\n* Concurrent serious diseases of liver, kidney, heart or other complications which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study. Any clinically relevant abnormal findings in vital sign or physical examination at Visit 1 in this study, which in the opinion of the investigator may put the patient at risk because of his/her participation in the study.\n* Pregnant or possible pregnancy or planning to become pregnant during the study period\n* Other subjects who are considered inappropriate to participate in this study judged by the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Adverse Events (AEs).","description":"AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Clinical Laboratory Test Values.","description":"Analysis of haematological, clinical chemistry and urynalysis variables were performed.\n\nHaematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count.\n\nClinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen.\n\nUrinalysis variables: protein, glucose, urobilinogen, occult.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Plasma Cortisol Values.","description":"Cut-off value of cortisol is defined as 4 mcg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Height","description":"Height, change from baseline calculated as (height at last visit - height at randomization)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.34","spread":"1.99"},{"groupId":"OG001","value":"6.35","spread":"1.89"}]}]}]},{"type":"SECONDARY","title":"Weight","description":"Weight, change from baseline calculated as (weight at last visit - weight at randomization)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.78","spread":"2.77"},{"groupId":"OG001","value":"4.39","spread":"3.22"}]}]}]},{"type":"SECONDARY","title":"Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal","description":"Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.54","spread":"19.87"},{"groupId":"OG001","value":"5.84","spread":"17.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)","description":"Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4.\n\n0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.139","spread":"0.334"},{"groupId":"OG001","value":"-0.156","spread":"0.302"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)","description":"Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization).\n\nScale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.29"},{"groupId":"OG001","value":"-0.147","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)","description":"Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.647"},{"groupId":"OG001","value":"-0.242","spread":"0.485"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)","description":"Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.415"},{"groupId":"OG001","value":"-0.097","spread":"0.368"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disturbance of Daily Activities","description":"Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization).\n\nFrequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.037","spread":"0.141"},{"groupId":"OG001","value":"-0.017","spread":"0.141"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disturbance of Night-time Sleep","description":"Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization).\n\nFrequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.029","spread":"0.134"},{"groupId":"OG001","value":"-0.042","spread":"0.132"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline","description":"Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 \\* (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"15.59"},{"groupId":"OG001","value":"2.31","spread":"16.63"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":121},"commonTop":["Upper Respiratory Tract Infection","Bronchitis","Pharyngitis","Gastroenteritis","Influenza"]}}}